publication date: Jun 29, 2012
|
author/source: ANDREW LLOYD & ASSOCIATES
Imaxio, a biopharmaceutical company specialized in the
areas of vaccines and genomics, announces today that it has reinforced its
capacity to prepare samples for high-throughput sequencing through the
acquisition of an Agilent Bravo automated liquid handling platform.
The new equipment will enable Imaxio to process a large number samples in a
fast turnaround time because of optimized protocols, notably for SureSelect and
Haloplex technologies offered on the Agilent Technologies platform. These
technologies enable researchers to capture and enrich specific sequences.
Imaxio's genomics platform has held Agilent Technologies' Certified Service
Provider status for microarray applications since 2009. At the end of 2011, it
acquired similar status for DNA and RNA target enrichment in next-generation
sequencing. Both awards were in recognition of the high-level of expertise and
skills of the Imaxio team.
Imaxio has boosted its already high-quality services in genomics to respond to
growing demand for high-throughput sequencing for clients particularly in the
clinical field but also in the pharmaceutical, cosmetics, agri-food, and
veterinary areas.
"Imaxio's investment in this new high-throughput sequencing platform
demonstrates our company's firm commitment to continually improving our genomic
services," said Veronique Vidal, director of the genomic department at Imaxio.
"The resulting improvement in our genomic services keeps pace with the
technological advances of the sector and our customers' requirements. The
sequencing market is very active and in perpetual technological evolution.
Imaxio's intimate knowledge and know-how in this area, as well as its optimized
protocols and automation, mean that Imaxio is well-placed to manage large-scale
projects."
"Through this investment, Imaxio is also strengthening its partnership with
Agilent Technologies," said Alexandre Le Vert, managing director at Imaxio. "In
parallel to this acquisition, we are delighted to announce the expansion of our
team with a new recruit, Michel Perriere, in charge of genomics development."
For more information, go to:
www.imaxio.com and
www.genomics-imaxio.com
About Imaxio SA
Imaxio SA is a biopharmaceutical company specialized in the areas of
vaccines and genomics. Imaxio's genomics division undertakes diagnostic and
therapeutic research in the field of oncology and immunology, as well as
providing services in the areas of human health, the agro-food business and the
environment.
Using its carrier protein technology (IMX313), Imaxio is developing, both
individually and with its partners, recombinant vaccines based on carrier
proteins for applications in both human and animal health. Carrier proteins are
used to improve the effectiveness of vaccines. In France, Imaxio already
markets Spirolept(R), a human vaccine against
leptospirosis.
Imaxio was created through the merger between Diagnogene and Avidis, a spin-off
from the Medical Research Council and Cambridge University in the UK. The
company owns well-founded intellectual property and collaborates with numerous
academic partners, including the Jenner Institute at Oxford University. Imaxio
SA is based in Lyon and at Saint Beauzire, near Clermont-Ferrand in France. It
has 24 employees, ten of whom are engaged in R&D. In 2011, it had a
turnover of EUR 2.4 million.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.